Is Biocon (BIOCON) overvalued or fairly valued?

MarketChacha shows Biocon's valuation in context — a forward P/E of about 36.1, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Biocon's revenue?

Biocon reported revenue of ₹2,346 Cr for FY2026, with net profit of ₹37 Cr, per official filings.

What is the share price of Biocon (BIOCON)?

Biocon last traded at ₹397.40 (-1.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Biocon

BIOCON · NSE · Pharma/Biotech · India

Snapshot

TickerBIOCON

ExchangeNSE

SectorPharma/Biotech

IndustryBiotechnology

CountryIndia

Employees16,447

HeadquartersBengaluru, India

Websitewww.biocon.com

Filings tracked17

About Biocon

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Who owns it

Promoters48.1%
Institutions32.5%
Public & other19.4%

107 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend4.1% → 2.3%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 11% · PAT -4%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,880 Cr · EPS 1.24

Est. earnings growth -54.7%

Next fiscal year

Rev ₹22,287 Cr · EPS 11.01

Est. earnings growth +61.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹16,927 Cr

Net margin

2.3%

Revenue CAGR (3y)

+14.8%

Profit CAGR (3y)

-5.9%

Net profit (FY2026)

₹386 Cr

Ask MarketChacha about BIOCON

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about BIOCON

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹16,927 Cr	₹386 Cr	2.3%
FY2025	₹15,262 Cr	₹1,013 Cr	6.6%
FY2024	₹14,756 Cr	₹1,023 Cr	6.9%
FY2023	₹11,174 Cr	₹463 Cr	4.1%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹4,336 Cr	₹141 Cr	3.3%
Q4 FY26	₹4,517 Cr	₹126 Cr	2.8%
Q3 FY26	₹4,173 Cr	₹144 Cr	3.4%
Q2 FY26	₹4,296 Cr	₹85 Cr	2.0%
Q1 FY26	₹3,942 Cr	₹31 Cr	0.8%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Communication Regarding Remittance Of Final Dividend For The FY 2025-26
Communication regarding remittance of final dividend for the FY 2025-26
BSE8/28/2026
Company Statement
Company Statement
BSE8/25/2026
Company Statement
Company Statement
BSE8/18/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results and Scrutinizer''s report
BSE8/8/2026material
Resignation of Statutory Auditors
Resignation of Statutory auditors of material subsidiaries of the Company.
BSE8/6/2026
Change in Directorate
Change in Directorate
BSE8/6/2026
Completion Of Tenure Of Statutory Auditors
Completion of tenure of Statutory Auditors
BSE8/6/2026
Appointment of Statutory Auditor/s
Appointment of Statutory Auditors
BSE8/6/2026
Change in Directorate
Change in Directorate
BSE8/6/2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 48th AGM of the Company and the Chairperson''s speech.
BSE8/6/2026material
Investor Presentation
Investor Presentation
BSE8/6/2026
Press Release / Media Release
Press Release
BSE8/3/2026
Commercial Launch Of Product
Commercial Launch of Product
BSE8/3/2026
Company Statement
Company Statement
BSE7/29/2026
Board Meeting Intimation for Intimation For The Board Meeting And Earnings Conference Call For Analysts And Investors
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation for the Board Meeting and ....
BSE7/28/2026material
Change in Directorate
Completion of tenure of Independent Director
BSE7/22/2026
Change in Directorate
Completion of tenure of Independent Director
BSE7/22/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.